questions to ask at agm, page-3

Relenza would (unfortunately) make an excellent case study on how NOT to market a product. And BTA an example of how NOT to market a company. Whereas Roche now have one of the world's most recognised drugs in tamiflu.

If this is the best they can do, I fear that Lani may become another "how NOT to" case study. Although being a JV does not help.

I think they sold their souls to GSK and may not be able to make any comments regarding relenza. They should at least be able to say something.

Ask

"seeing they have so much money coming in, have they thought of hiring a PR firm to promote Biota and its products?


Mal